BearingPoint Reports Outstanding Growth in 2017 with Revenues Reaching 710 Million Euros
BearingPoint announced today record revenues of 710 million euros in 2017, representing a 12% increase over the previous year. Bookings grew 14% year-on-year, showing strong momentum in business development. Consequently, the firm grew much faster than the 7% growth forecasted by research company Gartner for consulting worldwide in 20171. Regarding utilization rate, the firm ran at capacity and increased its workforce by 11% to allow for further growth. Despite significant investments in people and the creation of new IP-based assets, growth was highly profitable with an EBIT increase of 18% year over year. As a result, BearingPoint is set to reach its goal of one billion euros in revenues by 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180405005085/en/
Peter Mockler, Managing Partner BearingPoint (Photo: Business Wire)
“We certainly had a good market environment in 2017, but BearingPoint’s performance was particularly strong. It was the continued execution of the firm’s long-term strategy to combine business consulting, technology and IP-based assets that again paid off, and I am proud of what we achieved as a team. We are well on the way of reaching our goal of one billion euros in revenues by 2020,” says Peter Mockler, Managing Partner BearingPoint.
BearingPoint saw growth across all industry segments, service lines and regions, with the firm’s core territory EMEA again forming the stronghold. The Consulting unit showed strong overall performance and specific drivers of growth such as the firm’s products in Regulatory Technology stood out in the Solutions unit.
Investments in ecosystems creating new IP assets
BearingPoint continued to invest in innovative ecosystems and new IP assets that bring technologies, ideas and, financing together to create rapid solutions for changing market environments. Against this background, the firm acquired the supply-chain specialist LCP Consulting in the UK, integrated an automotive consulting team in Italy, and invested in the Norwegian insure-tech start-up Tribe. With its “Be an Innovator” process, BearingPoint generated more than 100 ideas for new services. Innovation labs were used to develop and validate innovative services with clients. BearingPoint created ten new Accelerators, the firm’s technology packages with rapid market impact, which led to 56 million euros in new bookings in 2017. The infrastructure of the firm’s Solutions unit was further developed to better match its focus on software products. It now also includes P&L responsibility to provide even more room for entrepreneurship in this unit.
Rapidly growing workforce anchored by client focus and stewardship
Driven by its strong growth, BearingPoint increased its workforce with new talent across all regions by 11% year-on-year. Also, 19 new Partners were admitted to the firm’s partnership: 16 were promoted internally and 3 joined from the market.
“Our workforce grew double-digit, and there is a good reason for our success in attracting talent. We understand that it’s all about the ecosystem of work: the company culture, the way you experience leadership, the quality of the projects you are working on, and the environment you are working in,” says Peter Mockler.
“Admitting new Partners to BearingPoint is also great news for our clients and for us. It’s great for our clients because the Partners are at the heart of our independent partnership. They make sure that we keep client focus as our first priority at all times. It’s also good news for us because stewardship is a core principle of our partnership: we are determined to develop our people and our capabilities in order to build a stronger, healthier, and wiser organization for the benefit of future generations of employees. I’m also happy to report that four of our newly appointed Partners were women, which was an important step toward our goal of 20% of Partners being female by 2020,” he adds.
Market recognition for innovative technologies
BearingPoint’s offerings for digital transformation and regulatory technology were recognized by leading analysts in 2017. IDC evaluated BearingPoint as a “Major Player” in its “MarketScape: EMEA Digital Strategy and Agency Services 2017 Vendor Assessment,” and Gartner named BearingPoint a “Visionary” in its 2017 “Magic Quadrant for Integrated Revenue and Customer Management for Communication Services Providers.” BearingPoint was also recognized as a “Visionary” in the Gartner “Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide” for the third consecutive time. The firm was honored with the Chartis RiskTech100® award in the category “Regulatory Reporting” as well as with the Central Banking award as “Consultancy and Advisory Services Provider of the Year.” In November 2017, BearingPoint was awarded the Salesforce Platinum Partner status as a result of successfully helping clients enhance their customer experience and run their businesses in the cloud.
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three units: Consulting, Solutions and Ventures. Consulting covers the advisory business; Solutions provides the tools for successful digital transformation, regulatory technology and advanced analytics; Ventures drives the financing and development of start-ups. BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 75 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
1 Source: Gartner. Forecast: IT Services, Worldwide, 2015-2021, 4Q17 Update. Published: December 19, 2017. ID: G00343324.
Tel.: +49 89 540338029
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00 | Tiedote
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10 | Tiedote
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13 | Tiedote
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00 | Tiedote
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41 | Tiedote
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00 | Tiedote
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme